Clinical trialPhase 2Terminated
Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study
The Impact of Total Intravenous Anesthesia Following Cancer Surgery (TIVACS) Study
- Outcome
- Stopped earlyPrincipal investigator departed sponsoring organization (Business decision)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 2 June 2023
- Expected end
- 26 January 2024
- Enrollment
- 8 participants
- Sites
- 1
- Primary outcomes
- Impact of Anesthetic Agent on Inflammation and Immunosuppression
- Sponsor
- Other
- Results posted
- 2025-07-10
- Last update
- 10 July 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This phase II trials studies the impact of total intravenous anesthesia (TIVA) following cancer surgery. Surgery and the anesthesia delivered causes physiologic stress and trauma resulting in immune suppression. TIVA is an alternative method of general anesthesia that has several benefits over volatile inhalation agents such as reducing nausea, vomiting, and opioid consumption, and promotes earlier return of bowel function following surgery. In addition, TIVA is less immunosuppressive than inhalational agents and has been shown to decrease cancer cell proliferation, migration, and metastasis formation. Giving TIVA during cancer-directed abdominal surgery may decrease the immunosuppressive state in the peri-surgical period.
Detailed description public domain (ClinicalTrials.gov)
PRIMARY OBJECTIVE: I. To evaluate the impact of anesthetic agent on inflammation and immunosuppression among patients undergoing abdominal cancer surgery. SECONDARY OBJECTIVE: I. To determine the impact of anesthetic choice on short-term anesthetic and surgical outcomes. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients undergo surgical resection with TIVA. ARM II: Patients undergo surgical resection with inhaled volatile anesthetics. After completion of study treatment, patients are followed up for up to 2 years.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Impact of Anesthetic Agent on Inflammation and Immunosuppression [Up to 2 years].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Impact of Anesthetic Choice on Short-term Anesthetic and Surgical Outcomes [Up to 2 years].